A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Registration Number
- JPRN-jRCT2080223391
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Must have histologic documentation of advanced solid tumors
- Must have received and have progressed, are refractory or, intolerant to standard therapy and must not have a curative therapy option
Exclusion Criteria
- Concurrent enrollment in another clinical study
- Prior participation in clinical studies that include durvalumab alone or in combination
- Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety<br>-
- Secondary Outcome Measures
Name Time Method safety<br>pharmacokinetics<br>-